American Society of Addiction Medicine
American Society of Addiction Medicine
Lead: Physician Reluctance to Intervene in Addiction: A Systematic Review
Lead: Physician Reluctance to Intervene in Addiction: A Systematic Review
Lead: Physician Reluctance to Intervene in Addiction: A Systematic Review
Tuesday 13th August 2024
Explore why physicians often avoid addressing addiction, with insights from a systematic review and studies on GLP1 agonists and supervised consumption services.
5 minutes
Informative
Educational
Supportive
Eye-opening
Engaging
About this podcast
Author:
American Society of Addiction Medicine
Overview:
Categories:
Innovative Treatments & Recovery Paths
Navigating Alcohol Dependency
Family Recovery from Addiction
Nutritional Pathways to Recovery
Navigating Intimate Relationships
Links:
Visit site
Episodes:
131 (View all)
Do you want to link to this podcast?
Get the buttons here!Why Doctors Hesitate: Unpacking Physician Reluctance in Addiction Care
Episode Overview
- Institutional environment is a major barrier to physician intervention in addiction.
- Lack of skill, cognitive capacity, and knowledge also contribute to physician reluctance.
- GLP1 agonists show mixed results in treating substance use disorders.
- Patients with worse baseline mental health often have poorer treatment outcomes.
- Supervised consumption services may help mitigate increases in overdose deaths.
"Improving institutional support and providing better training could make a significant difference."
Ever wondered why some doctors hesitate to address addiction in their practice? This episode of 'This Week in Addiction Medicine' tackles that very question. The main discussion centres around a systematic review from JAMA Network Open, which examined 283 articles to understand why physicians often avoid intervening in addiction cases. The findings are eye-opening - institutional environment tops the list, with lack of skill, cognitive capacity, and knowledge following closely behind.
It's clear that improving institutional support and providing better training could make a significant difference. The episode doesn't stop there. It also dives into a study on the efficacy of GLP1 agonists in treating various substance use disorders. The results are mixed, but they offer valuable insights into potential treatment avenues for tobacco, alcohol, and cocaine use disorders.
Another intriguing segment covers a latent profile analysis of patients in residential treatment, revealing that those with worse baseline mental health tend to have poorer outcomes. This highlights the need for more comprehensive strategies to address comorbid conditions. You'll also hear about a study from Ontario, Canada, evaluating the impact of supervised consumption services (SCS) on opioid-related mortality and morbidity.
While SCS didn't significantly reduce deaths or hospital visits at the population level, they might have mitigated increases in overdose deaths. The episode wraps up with a case report on buprenorphine naloxone, discussing its side effects and potential alternatives for better treatment retention. If you're keen on understanding the complexities of addiction medicine and the barriers that healthcare professionals face, this episode is a must-listen.
It's packed with data-driven insights and practical takeaways that could reshape how addiction care is approached.